KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Net Income - Minority (2016 - 2019)

Historic Net Income - Minority for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$21.8 billion.

  • Gsk's Net Income - Minority fell 1969.07% to -$21.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.8 billion, marking a year-over-year decrease of 1969.07%. This contributed to the annual value of -$17.5 billion for FY2024, which is 526.46% down from last year.
  • Per Gsk's latest filing, its Net Income - Minority stood at -$21.8 billion for Q3 2025, which was down 1969.07% from -$19.7 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's Net Income - Minority peaked at -$10.8 billion during Q3 2022, and registered a low of -$21.8 billion during Q3 2025.
  • In the last 5 years, Gsk's Net Income - Minority had a median value of -$18.2 billion in 2024 and averaged -$18.2 billion.
  • As far as peak fluctuations go, Gsk's Net Income - Minority skyrocketed by 4928.03% in 2022, and later tumbled by 3326.41% in 2023.
  • Quarter analysis of 5 years shows Gsk's Net Income - Minority stood at -$20.3 billion in 2021, then soared by 38.75% to -$12.4 billion in 2022, then crashed by 33.26% to -$16.6 billion in 2023, then decreased by 5.92% to -$17.5 billion in 2024, then dropped by 24.15% to -$21.8 billion in 2025.
  • Its Net Income - Minority stands at -$21.8 billion for Q3 2025, versus -$19.7 billion for Q2 2025 and -$17.8 billion for Q1 2025.